JP2019517455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517455A5 JP2019517455A5 JP2018552704A JP2018552704A JP2019517455A5 JP 2019517455 A5 JP2019517455 A5 JP 2019517455A5 JP 2018552704 A JP2018552704 A JP 2018552704A JP 2018552704 A JP2018552704 A JP 2018552704A JP 2019517455 A5 JP2019517455 A5 JP 2019517455A5
- Authority
- JP
- Japan
- Prior art keywords
- sulfonyl
- benzene
- trifluoromethoxy
- pyridin
- oxadiazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 43
- 150000003839 salts Chemical class 0.000 claims 23
- 125000005843 halogen group Chemical group 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 15
- 229940124597 therapeutic agent Drugs 0.000 claims 13
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 12
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 201000003883 Cystic fibrosis Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims 3
- WOXOLLSAICIZNO-UHFFFAOYSA-N [5-[3-amino-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=NN=C(O1)CO WOXOLLSAICIZNO-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- RGSUYUQKDFLNQY-SFHVURJKSA-N (1S)-1-[5-[3-amino-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]-2-phenylethanol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=NN=C(O1)[C@H](CC1=CC=CC=C1)O RGSUYUQKDFLNQY-SFHVURJKSA-N 0.000 claims 1
- SVIYEFBUSOAYQQ-OAHLLOKOSA-N (2S)-2-[5-[3-amino-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-thiadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=NN=C(S1)[C@@](C(F)(F)F)(C)O SVIYEFBUSOAYQQ-OAHLLOKOSA-N 0.000 claims 1
- QPUMSIZJBUZSSL-SFHVURJKSA-N (S)-[5-[3-amino-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]-phenylmethanol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=NN=C(O1)[C@@H](O)C1=CC=CC=C1 QPUMSIZJBUZSSL-SFHVURJKSA-N 0.000 claims 1
- LFAWOLKBIDEZBO-UHFFFAOYSA-N 1-[5-[3-amino-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]-2,2,2-trifluoroethanol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=NN=C(O1)C(C(F)(F)F)O LFAWOLKBIDEZBO-UHFFFAOYSA-N 0.000 claims 1
- NOCHSTYDJNONRL-UHFFFAOYSA-N 2-(1,3,4-oxadiazol-2-yl)-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound O1C(=NN=C1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F NOCHSTYDJNONRL-UHFFFAOYSA-N 0.000 claims 1
- QVAWYCHUIQRKMJ-UHFFFAOYSA-N 2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound C1(CC1)C1=NOC(=N1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F QVAWYCHUIQRKMJ-UHFFFAOYSA-N 0.000 claims 1
- SEWTVVBWCIBCRT-UHFFFAOYSA-N 2-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound C(C)(C)(C)C1=NOC(=N1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F SEWTVVBWCIBCRT-UHFFFAOYSA-N 0.000 claims 1
- AHVWESHVIPMZFV-UHFFFAOYSA-N 2-(5-cyclohexyl-1,3,4-oxadiazol-2-yl)-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound C1(CCCCC1)C1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F AHVWESHVIPMZFV-UHFFFAOYSA-N 0.000 claims 1
- UBATUHAOKRVMRY-UHFFFAOYSA-N 2-[3-(1-methoxyethyl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound COC(C)C1=NOC(=N1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F UBATUHAOKRVMRY-UHFFFAOYSA-N 0.000 claims 1
- RWANNJNFJWJZRJ-UHFFFAOYSA-N 2-[3-(2-methoxyethyl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound COCCC1=NOC(=N1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F RWANNJNFJWJZRJ-UHFFFAOYSA-N 0.000 claims 1
- TUPQCDKYEKGCIY-UHFFFAOYSA-N 2-[3-(2-methoxypropan-2-yl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound COC(C)(C)C1=NOC(=N1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F TUPQCDKYEKGCIY-UHFFFAOYSA-N 0.000 claims 1
- BUMHFKUWKSVQSA-UHFFFAOYSA-N 2-[3-(cyclopropylmethyl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound C1(CC1)CC1=NOC(=N1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F BUMHFKUWKSVQSA-UHFFFAOYSA-N 0.000 claims 1
- LRNHXRYWRCFIIT-UHFFFAOYSA-N 2-[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound COCC1=NOC(=N1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F LRNHXRYWRCFIIT-UHFFFAOYSA-N 0.000 claims 1
- HGQIDXBJNFJGFS-UHFFFAOYSA-N 2-[3-(oxan-4-yl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound O1CCC(CC1)C1=NOC(=N1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F HGQIDXBJNFJGFS-UHFFFAOYSA-N 0.000 claims 1
- UOCUMVVRLXUYPK-UHFFFAOYSA-N 2-[3-(oxolan-2-ylmethyl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound O1C(CCC1)CC1=NOC(=N1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F UOCUMVVRLXUYPK-UHFFFAOYSA-N 0.000 claims 1
- LKFHQKZRUJXMPV-UHFFFAOYSA-N 2-[3-(oxolan-3-yl)-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound O1CC(CC1)C1=NOC(=N1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F LKFHQKZRUJXMPV-UHFFFAOYSA-N 0.000 claims 1
- ZXXXGUCODUSSIG-UHFFFAOYSA-N 2-[3-[(4-fluorophenoxy)methyl]-1,2,4-oxadiazol-5-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical class FC1=CC=C(OCC2=NOC(=N2)C2=NC=C(C=C2N)S(=O)(=O)C2=CC=C(C=C2)OC(F)(F)F)C=C1 ZXXXGUCODUSSIG-UHFFFAOYSA-N 0.000 claims 1
- UCPNPZINHHQZMN-UHFFFAOYSA-N 2-[5-(1-methoxyethyl)-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound COC(C)C1=NN=C(S1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F UCPNPZINHHQZMN-UHFFFAOYSA-N 0.000 claims 1
- AKRJGNVFXMPYSH-UHFFFAOYSA-N 2-[5-(2-methoxyethoxymethyl)-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical class COCCOCC1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F AKRJGNVFXMPYSH-UHFFFAOYSA-N 0.000 claims 1
- GSAJFWCFBNZIML-UHFFFAOYSA-N 2-[5-(2-methoxyethoxymethyl)-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound COCCOCC1=NN=C(S1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F GSAJFWCFBNZIML-UHFFFAOYSA-N 0.000 claims 1
- POKPEGLINWBQAD-UHFFFAOYSA-N 2-[5-(cyclopentyloxymethyl)-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound C1(CCCC1)OCC1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F POKPEGLINWBQAD-UHFFFAOYSA-N 0.000 claims 1
- FRGNYTVRPHEJRF-UHFFFAOYSA-N 2-[5-(cyclopropylmethoxymethyl)-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound C1(CC1)COCC1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F FRGNYTVRPHEJRF-UHFFFAOYSA-N 0.000 claims 1
- VMPDWAQANSTYGC-UHFFFAOYSA-N 2-[5-(cyclopropylmethoxymethyl)-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound C1(CC1)COCC1=NN=C(S1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F VMPDWAQANSTYGC-UHFFFAOYSA-N 0.000 claims 1
- IBEXDKLPODXXFV-UHFFFAOYSA-N 2-[5-(difluoromethoxymethyl)-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound FC(OCC1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)F IBEXDKLPODXXFV-UHFFFAOYSA-N 0.000 claims 1
- LZKVQYYFICZDPG-UHFFFAOYSA-N 2-[5-(difluoromethoxymethyl)-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound FC(OCC1=NN=C(S1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)F LZKVQYYFICZDPG-UHFFFAOYSA-N 0.000 claims 1
- FNEJIYILPURCDR-UHFFFAOYSA-N 2-[5-(ethoxymethyl)-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound C(C)OCC1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F FNEJIYILPURCDR-UHFFFAOYSA-N 0.000 claims 1
- BRHOUGDTPGNTNG-UHFFFAOYSA-N 2-[5-(ethoxymethyl)-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound C(C)OCC1=NN=C(S1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F BRHOUGDTPGNTNG-UHFFFAOYSA-N 0.000 claims 1
- DJAIUIVMCKEZFW-UHFFFAOYSA-N 2-[5-(methoxymethyl)-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound COCC1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F DJAIUIVMCKEZFW-UHFFFAOYSA-N 0.000 claims 1
- TTXUSZZEPMIWNA-UHFFFAOYSA-N 2-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound COCC1=NN=C(S1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F TTXUSZZEPMIWNA-UHFFFAOYSA-N 0.000 claims 1
- YQXUIYMCXKHUGP-UHFFFAOYSA-N 2-[5-(oxolan-3-yloxymethyl)-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound O1CC(CC1)OCC1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F YQXUIYMCXKHUGP-UHFFFAOYSA-N 0.000 claims 1
- PJGGPWZLFIHYAP-UHFFFAOYSA-N 2-[5-(oxolan-3-yloxymethyl)-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound O1CC(CC1)OCC1=NN=C(S1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F PJGGPWZLFIHYAP-UHFFFAOYSA-N 0.000 claims 1
- PZJMEMHATZSNGM-UHFFFAOYSA-N 2-[5-(phenoxymethyl)-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound O(C1=CC=CC=C1)CC1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F PZJMEMHATZSNGM-UHFFFAOYSA-N 0.000 claims 1
- GIQYLDYUYDLUEO-UHFFFAOYSA-N 2-[5-(pyridin-3-yloxymethyl)-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound N1=CC(=CC=C1)OCC1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F GIQYLDYUYDLUEO-UHFFFAOYSA-N 0.000 claims 1
- JXHWXDVYBQPQMF-UHFFFAOYSA-N 2-[5-(pyridin-3-yloxymethyl)-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound N1=CC(=CC=C1)OCC1=NN=C(S1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F JXHWXDVYBQPQMF-UHFFFAOYSA-N 0.000 claims 1
- GOJAZAKMRYUGBQ-UHFFFAOYSA-N 2-[5-(trifluoromethoxymethyl)-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound FC(OC1=CC=C(C=C1)S(=O)(=O)C=1C=C(C(=NC=1)C=1OC(=NN=1)COC(F)(F)F)N)(F)F GOJAZAKMRYUGBQ-UHFFFAOYSA-N 0.000 claims 1
- BZWLMHFXJAJTNO-UHFFFAOYSA-N 2-[5-(trifluoromethoxymethyl)-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound FC(OC1=CC=C(C=C1)S(=O)(=O)C=1C=C(C(=NC=1)C=1SC(=NN=1)COC(F)(F)F)N)(F)F BZWLMHFXJAJTNO-UHFFFAOYSA-N 0.000 claims 1
- YJJFTJLRAPICTB-SECBINFHSA-N 2-[5-[(1R)-1-methoxyethyl]-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound CO[C@H](C)C1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F YJJFTJLRAPICTB-SECBINFHSA-N 0.000 claims 1
- UCPNPZINHHQZMN-SECBINFHSA-N 2-[5-[(1R)-1-methoxyethyl]-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound CO[C@H](C)C1=NN=C(S1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F UCPNPZINHHQZMN-SECBINFHSA-N 0.000 claims 1
- YJJFTJLRAPICTB-VIFPVBQESA-N 2-[5-[(1S)-1-methoxyethyl]-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound CO[C@@H](C)C1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F YJJFTJLRAPICTB-VIFPVBQESA-N 0.000 claims 1
- UCPNPZINHHQZMN-VIFPVBQESA-N 2-[5-[(1S)-1-methoxyethyl]-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound CO[C@@H](C)C1=NN=C(S1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F UCPNPZINHHQZMN-VIFPVBQESA-N 0.000 claims 1
- BUGJLENFQSLSGB-IBGZPJMESA-N 2-[5-[(S)-methoxy(phenyl)methyl]-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound CO[C@H](C1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=CC=CC=C1 BUGJLENFQSLSGB-IBGZPJMESA-N 0.000 claims 1
- OGZGCQWOENEPJW-IBGZPJMESA-N 2-[5-[(S)-methoxy(phenyl)methyl]-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical class CO[C@H](C1=NN=C(S1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=CC=CC=C1 OGZGCQWOENEPJW-IBGZPJMESA-N 0.000 claims 1
- RJRCXNXWAMTUFE-UHFFFAOYSA-N 2-[5-[3-amino-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]-1,1,1-trifluoropropan-2-ol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=NN=C(O1)C(C(F)(F)F)(C)O RJRCXNXWAMTUFE-UHFFFAOYSA-N 0.000 claims 1
- XNCPIZTZFQCDAR-GFCCVEGCSA-N 2-[5-[[(2R)-oxolan-2-yl]methyl]-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound O1[C@H](CCC1)CC1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F XNCPIZTZFQCDAR-GFCCVEGCSA-N 0.000 claims 1
- HGOMTAXEHIQMMW-GFCCVEGCSA-N 2-[5-[[(2R)-oxolan-2-yl]methyl]-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound O1[C@H](CCC1)CC1=NN=C(S1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F HGOMTAXEHIQMMW-GFCCVEGCSA-N 0.000 claims 1
- XNCPIZTZFQCDAR-LBPRGKRZSA-N 2-[5-[[(2S)-oxolan-2-yl]methyl]-1,3,4-oxadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound O1[C@@H](CCC1)CC1=NN=C(O1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F XNCPIZTZFQCDAR-LBPRGKRZSA-N 0.000 claims 1
- HGOMTAXEHIQMMW-LBPRGKRZSA-N 2-[5-[[(2S)-oxolan-2-yl]methyl]-1,3,4-thiadiazol-2-yl]-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-3-amine Chemical compound O1[C@@H](CCC1)CC1=NN=C(S1)C1=NC=C(C=C1N)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F HGOMTAXEHIQMMW-LBPRGKRZSA-N 0.000 claims 1
- XCGIKWGGYZTWLG-UHFFFAOYSA-N 5-[3-amino-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazole-2-carboxamide Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=NN=C(O1)C(=O)N XCGIKWGGYZTWLG-UHFFFAOYSA-N 0.000 claims 1
- AMBUCGCQNZDDOC-UHFFFAOYSA-N 5-amino-N-benzyl-6-[5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl]-N-methylpyridine-3-sulfonamide Chemical compound NC=1C=C(C=NC=1C=1OC(=NN=1)CO)S(=O)(=O)N(C)CC1=CC=CC=C1 AMBUCGCQNZDDOC-UHFFFAOYSA-N 0.000 claims 1
- WZUNUMFWLBDZQY-UHFFFAOYSA-N CCC1=NOC(=N1)C2=C(C=C(C=N2)S(=O)(=O)C3=CC=C(C=C3)OC(F)(F)F)N Chemical compound CCC1=NOC(=N1)C2=C(C=C(C=N2)S(=O)(=O)C3=CC=C(C=C3)OC(F)(F)F)N WZUNUMFWLBDZQY-UHFFFAOYSA-N 0.000 claims 1
- XUJHPOBJPUEDIA-UHFFFAOYSA-N N-[[5-[3-amino-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-thiadiazol-2-yl]methyl]cyclopropanecarbothioamide Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=NN=C(S1)CNC(=S)C1CC1 XUJHPOBJPUEDIA-UHFFFAOYSA-N 0.000 claims 1
- QDLWEAFULOKMPL-UHFFFAOYSA-N [2-[3-amino-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3-thiazol-5-yl]methanol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C=1SC(=CN=1)CO QDLWEAFULOKMPL-UHFFFAOYSA-N 0.000 claims 1
- FTKLVTLVDZVGQZ-UHFFFAOYSA-N [5-[3-amino-4-bromo-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol Chemical compound NC=1C(=NC=C(C=1Br)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=NN=C(O1)CO FTKLVTLVDZVGQZ-UHFFFAOYSA-N 0.000 claims 1
- GYKQLROARLMIRH-UHFFFAOYSA-N [5-[3-amino-4-chloro-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol Chemical compound NC=1C(=NC=C(C=1Cl)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=NN=C(O1)CO GYKQLROARLMIRH-UHFFFAOYSA-N 0.000 claims 1
- JRTJKHDJHXHEOJ-UHFFFAOYSA-N [5-[3-amino-5-(2-propan-2-ylphenyl)sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=C(C=CC=C1)C(C)C)C1=NN=C(O1)CO JRTJKHDJHXHEOJ-UHFFFAOYSA-N 0.000 claims 1
- JTEFEPMGHHACNE-UHFFFAOYSA-N [5-[3-amino-5-(4-fluorophenyl)sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)F)C1=NN=C(O1)CO JTEFEPMGHHACNE-UHFFFAOYSA-N 0.000 claims 1
- GYASKYYQXOMZFG-UHFFFAOYSA-N [5-[3-amino-5-(benzenesulfonyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=CC=C1)C1=NN=C(O1)CO GYASKYYQXOMZFG-UHFFFAOYSA-N 0.000 claims 1
- DZEOJINSUBCKKO-UHFFFAOYSA-N [5-[3-amino-5-[2-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=C(C=CC=C1)OC(F)(F)F)C1=NN=C(O1)CO DZEOJINSUBCKKO-UHFFFAOYSA-N 0.000 claims 1
- WWCUBNPYXAHVDM-UHFFFAOYSA-N [5-[3-amino-5-[3-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC(=CC=C1)OC(F)(F)F)C1=NN=C(O1)CO WWCUBNPYXAHVDM-UHFFFAOYSA-N 0.000 claims 1
- UTHFGDNAWQQTRG-UHFFFAOYSA-N [5-[3-amino-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methyl dihydrogen phosphate Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)C1=NN=C(O1)COP(=O)(O)O UTHFGDNAWQQTRG-UHFFFAOYSA-N 0.000 claims 1
- QOBGZADYMZJBMX-UHFFFAOYSA-N [5-[3-amino-5-[4-(trifluoromethyl)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)C(F)(F)F)C1=NN=C(O1)CO QOBGZADYMZJBMX-UHFFFAOYSA-N 0.000 claims 1
- BWOVMANFDLPAQC-UHFFFAOYSA-N [5-[3-amino-5-[4-(trifluoromethyl)phenyl]sulfonylpyridin-2-yl]-1,3,4-thiadiazol-2-yl]methanol Chemical compound NC=1C(=NC=C(C=1)S(=O)(=O)C1=CC=C(C=C1)C(F)(F)F)C1=NN=C(S1)CO BWOVMANFDLPAQC-UHFFFAOYSA-N 0.000 claims 1
- KIZHWZGREZYJNC-UHFFFAOYSA-N [5-[3-amino-6-bromo-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol Chemical compound NC=1C(=NC(=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)Br)C1=NN=C(O1)CO KIZHWZGREZYJNC-UHFFFAOYSA-N 0.000 claims 1
- UYZOEJUWGLJKHZ-UHFFFAOYSA-N [5-[3-amino-6-chloro-5-[4-(trifluoromethoxy)phenyl]sulfonylpyridin-2-yl]-1,3,4-oxadiazol-2-yl]methanol Chemical compound NC=1C(=NC(=C(C=1)S(=O)(=O)C1=CC=C(C=C1)OC(F)(F)F)Cl)C1=NN=C(O1)CO UYZOEJUWGLJKHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021173679A JP7392211B2 (ja) | 2016-06-03 | 2021-10-25 | ヘテロアリール置換されたピリジン類及び使用方法 |
| JP2023049450A JP7622122B2 (ja) | 2016-06-03 | 2023-03-27 | ヘテロアリール置換されたピリジン類及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345315P | 2016-06-03 | 2016-06-03 | |
| US62/345,315 | 2016-06-03 | ||
| PCT/IB2017/053068 WO2017208115A1 (en) | 2016-06-03 | 2017-05-24 | Heteroaryl substituted pyridines and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173679A Division JP7392211B2 (ja) | 2016-06-03 | 2021-10-25 | ヘテロアリール置換されたピリジン類及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517455A JP2019517455A (ja) | 2019-06-24 |
| JP2019517455A5 true JP2019517455A5 (OSRAM) | 2020-06-25 |
| JP6968094B2 JP6968094B2 (ja) | 2021-11-17 |
Family
ID=59014678
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552704A Active JP6968094B2 (ja) | 2016-06-03 | 2017-05-24 | ヘテロアリール置換されたピリジン類及び使用方法 |
| JP2021173679A Active JP7392211B2 (ja) | 2016-06-03 | 2021-10-25 | ヘテロアリール置換されたピリジン類及び使用方法 |
| JP2023049450A Active JP7622122B2 (ja) | 2016-06-03 | 2023-03-27 | ヘテロアリール置換されたピリジン類及び使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173679A Active JP7392211B2 (ja) | 2016-06-03 | 2021-10-25 | ヘテロアリール置換されたピリジン類及び使用方法 |
| JP2023049450A Active JP7622122B2 (ja) | 2016-06-03 | 2023-03-27 | ヘテロアリール置換されたピリジン類及び使用方法 |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10138227B2 (OSRAM) |
| EP (1) | EP3464282B1 (OSRAM) |
| JP (3) | JP6968094B2 (OSRAM) |
| KR (2) | KR102719916B1 (OSRAM) |
| CN (2) | CN114671864B (OSRAM) |
| AR (2) | AR108672A1 (OSRAM) |
| AU (3) | AU2017273215B2 (OSRAM) |
| CA (1) | CA3022216A1 (OSRAM) |
| CL (1) | CL2018003323A1 (OSRAM) |
| CO (1) | CO2018012171A2 (OSRAM) |
| CR (1) | CR20180547A (OSRAM) |
| CY (1) | CY1124031T1 (OSRAM) |
| DK (1) | DK3464282T3 (OSRAM) |
| DO (1) | DOP2018000257A (OSRAM) |
| EC (1) | ECSP18094790A (OSRAM) |
| ES (1) | ES2806873T3 (OSRAM) |
| HR (1) | HRP20201068T1 (OSRAM) |
| HU (1) | HUE050248T2 (OSRAM) |
| IL (3) | IL303196B2 (OSRAM) |
| LT (1) | LT3464282T (OSRAM) |
| MX (2) | MX385054B (OSRAM) |
| MY (1) | MY199604A (OSRAM) |
| PE (1) | PE20190511A1 (OSRAM) |
| PH (1) | PH12018502534B1 (OSRAM) |
| PL (1) | PL3464282T3 (OSRAM) |
| PT (1) | PT3464282T (OSRAM) |
| RS (1) | RS60574B1 (OSRAM) |
| RU (2) | RU2021127810A (OSRAM) |
| SG (1) | SG11201808842VA (OSRAM) |
| SI (1) | SI3464282T1 (OSRAM) |
| SM (1) | SMT202000394T1 (OSRAM) |
| TW (4) | TWI752961B (OSRAM) |
| UY (2) | UY37272A (OSRAM) |
| WO (1) | WO2017208115A1 (OSRAM) |
| ZA (1) | ZA201808423B (OSRAM) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100921397B1 (ko) * | 2009-02-09 | 2009-10-14 | (주)오엠티 | 인쇄회로기판의 세척장비 및 이를 이용한 세척방법 |
| PT3203840T (pt) | 2014-10-06 | 2020-10-27 | Vertex Pharma | Moduladores do regulador da condutância transmembranar da fibrose quística |
| US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| LT3519401T (lt) | 2016-09-30 | 2021-11-25 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas |
| MX2021013639A (es) | 2016-12-09 | 2022-09-30 | Vertex Pharma | Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística. |
| WO2018116185A1 (en) | 2016-12-20 | 2018-06-28 | AbbVie S.à.r.l. | Deuterated cftr modulators and methods of use |
| TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
| CA3066084A1 (en) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CN111051280B (zh) | 2017-08-02 | 2023-12-22 | 弗特克斯药品有限公司 | 制备吡咯烷化合物的方法 |
| US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| TWI719349B (zh) | 2017-10-19 | 2021-02-21 | 美商維泰克斯製藥公司 | Ｃｆｔｒ調節劑之結晶形式及組合物 |
| MA51039A (fr) | 2017-12-08 | 2020-10-14 | Vertex Pharma | Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| SI3752510T1 (sl) | 2018-02-15 | 2023-03-31 | Vertex Pharmaceuticals Incorporated | Makrocikli kot modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki iz le-teh, njihova uporaba pri zdravljenju cistične fibroze in postopek za njihovo proizvodnjo |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| IT201900000687A1 (it) * | 2019-01-16 | 2020-07-16 | Fondazione St Italiano Tecnologia | Composti e composizioni per il trattamento della fibrosi cistica |
| AR118555A1 (es) | 2019-04-03 | 2021-10-20 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| EP3747882A1 (en) | 2019-06-03 | 2020-12-09 | AbbVie Overseas S.à r.l. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| WO2021011327A1 (en) | 2019-07-12 | 2021-01-21 | Orphomed, Inc. | Compound for treating cystic fibrosis |
| SI4013741T1 (sl) | 2019-08-14 | 2024-06-28 | Vertex Pharmaceuticals Incorporated | Postopek za izdelavo cftr-modulatorjev |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| CA3150162A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| IL292966A (en) * | 2019-11-12 | 2022-07-01 | Genzyme Corp | Heteroarylaminosulfonamides with 5 positions and methods of using them |
| US20230277550A1 (en) | 2020-08-20 | 2023-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for Treating Respiratory Diseases Characterized by Mucus Hypersecretion |
| EP4259139A1 (en) | 2020-12-10 | 2023-10-18 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US20220213041A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
| EP4274828A1 (en) | 2021-01-06 | 2023-11-15 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| KR20240041946A (ko) | 2021-08-19 | 2024-04-01 | 신젠타 크롭 프로텍션 아게 | 디아미드 저항성 해충을 방제하는 방법 및 그를 위한 화합물 |
| KR20250084132A (ko) | 2022-09-15 | 2025-06-10 | 이도르시아 파마슈티컬스 리미티드 | 마크로시클릭 cftr 조절제 |
| WO2024056791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
| CN116813569B (zh) * | 2023-07-10 | 2024-07-02 | 衡阳市中心医院 | 一种抗癌药中间体的制备方法和抗癌药的制备方法 |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2561560A1 (en) * | 2004-03-30 | 2005-10-13 | The Regents Of The University Of California | Hydrazide-containing cftr inhibitor compounds and uses thereof |
| AU2005251745A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| PL2489659T3 (pl) | 2004-06-24 | 2018-06-29 | Vertex Pharma | Modulatory transporterów posiadających kasetę wiążącą atp |
| BRPI0809498A2 (pt) * | 2007-04-02 | 2014-09-23 | Inst Oneworld Health | Compostos inibidores de cftr e seus usos |
| NZ581419A (en) | 2007-05-25 | 2012-05-25 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| ES2654395T3 (es) | 2007-12-10 | 2018-02-13 | Novartis Ag | Análogos de amilorida espirocíclicos como bloqueantes de ENaC |
| NZ586271A (en) | 2007-12-13 | 2012-08-31 | Vertex Pharma | Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator |
| US8436014B2 (en) | 2008-10-23 | 2013-05-07 | Vertex Pharmaceutical Incorporated | Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide |
| SI2349263T1 (sl) * | 2008-10-23 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Modulatorji cistiäśno-fibroznega transmembranskega regulatorja prevodnosti |
| WO2010078103A1 (en) | 2008-12-30 | 2010-07-08 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2011008931A2 (en) * | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| US8247436B2 (en) * | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| BR112013007907A2 (pt) | 2010-10-08 | 2016-06-14 | N30 Pharmaceuticals Inc | novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase |
| WO2012154880A1 (en) * | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
| US9034879B2 (en) | 2011-09-16 | 2015-05-19 | Novartis Ag | Heterocyclic compounds for the treatment of CF |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013043720A1 (en) | 2011-09-20 | 2013-03-28 | The University Of North Carolina At Chapel Hill | Regulation of sodium channels by plunc proteins |
| US9382254B2 (en) | 2013-05-07 | 2016-07-05 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis |
| DK3030568T3 (en) | 2013-08-08 | 2019-01-07 | Galapagos Nv | THIENO [2,3-C] PYRANES AS CFTR MODULATORS |
| WO2015138934A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| CA2942386A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| AU2015339196A1 (en) | 2014-10-31 | 2017-05-11 | Abbvie S.A.R.L. | Substituted tetrahydropyrans and method of use |
| JP6676646B2 (ja) | 2014-10-31 | 2020-04-08 | アッヴィ・エス・ア・エール・エル | 置換クロマンおよび使用方法 |
| US10196384B2 (en) * | 2015-03-31 | 2019-02-05 | Vertex Pharmaceuticals (Europe) Limited | Deuterated CFTR modulators |
| BR112017026132A2 (pt) * | 2015-06-02 | 2018-08-28 | AbbVie S.à.r.l. | piridinas substituídas e métodos de uso |
| US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
| CN108431002A (zh) | 2015-10-09 | 2018-08-21 | 艾伯维公司 | 取代的吡唑并[3，4-b]吡啶-6-甲酸及其用途 |
| PT3359541T (pt) | 2015-10-09 | 2020-11-11 | Galapagos Nv | Pirazol[3,4-b]piridin-6-carboxamidas n-sulfoniladas e método de utilização |
| BR112018072047A2 (pt) | 2016-04-26 | 2019-02-12 | AbbVie S.à.r.l. | moduladores da proteína reguladora de condutância transmembranar de fibrose cística |
| US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
-
2017
- 2017-05-23 US US15/602,892 patent/US10138227B2/en active Active
- 2017-05-24 HR HRP20201068TT patent/HRP20201068T1/hr unknown
- 2017-05-24 ES ES17728272T patent/ES2806873T3/es active Active
- 2017-05-24 RU RU2021127810A patent/RU2021127810A/ru unknown
- 2017-05-24 CR CR20180547A patent/CR20180547A/es unknown
- 2017-05-24 DK DK17728272.0T patent/DK3464282T3/da active
- 2017-05-24 AU AU2017273215A patent/AU2017273215B2/en active Active
- 2017-05-24 RS RS20200829A patent/RS60574B1/sr unknown
- 2017-05-24 HU HUE17728272A patent/HUE050248T2/hu unknown
- 2017-05-24 MX MX2018014758A patent/MX385054B/es unknown
- 2017-05-24 SG SG11201808842VA patent/SG11201808842VA/en unknown
- 2017-05-24 WO PCT/IB2017/053068 patent/WO2017208115A1/en not_active Ceased
- 2017-05-24 IL IL303196A patent/IL303196B2/en unknown
- 2017-05-24 SM SM20200394T patent/SMT202000394T1/it unknown
- 2017-05-24 KR KR1020227040379A patent/KR102719916B1/ko active Active
- 2017-05-24 CN CN202210433324.9A patent/CN114671864B/zh active Active
- 2017-05-24 PE PE2018003091A patent/PE20190511A1/es unknown
- 2017-05-24 KR KR1020187031861A patent/KR102469995B1/ko active Active
- 2017-05-24 MY MYPI2018703798A patent/MY199604A/en unknown
- 2017-05-24 EP EP17728272.0A patent/EP3464282B1/en active Active
- 2017-05-24 LT LTEP17728272.0T patent/LT3464282T/lt unknown
- 2017-05-24 JP JP2018552704A patent/JP6968094B2/ja active Active
- 2017-05-24 IL IL288243A patent/IL288243B2/en unknown
- 2017-05-24 PT PT177282720T patent/PT3464282T/pt unknown
- 2017-05-24 CA CA3022216A patent/CA3022216A1/en active Pending
- 2017-05-24 CN CN201780033214.0A patent/CN109311864B/zh active Active
- 2017-05-24 RU RU2018138707A patent/RU2756743C2/ru active
- 2017-05-24 PL PL17728272T patent/PL3464282T3/pl unknown
- 2017-05-24 SI SI201730320T patent/SI3464282T1/sl unknown
- 2017-06-02 UY UY0001037272A patent/UY37272A/es active IP Right Grant
- 2017-06-02 UY UY0001040612A patent/UY40612A/es not_active Application Discontinuation
- 2017-06-02 AR ARP170101516A patent/AR108672A1/es active IP Right Grant
- 2017-06-03 TW TW106118418A patent/TWI752961B/zh active
- 2017-06-03 TW TW112108367A patent/TWI849782B/zh active
- 2017-06-03 TW TW110149319A patent/TWI797926B/zh active
- 2017-06-03 TW TW113122971A patent/TW202515560A/zh unknown
-
2018
- 2018-10-16 IL IL262415A patent/IL262415B/en unknown
- 2018-10-19 US US16/165,662 patent/US10604515B2/en active Active
- 2018-11-13 CO CONC2018/0012171A patent/CO2018012171A2/es unknown
- 2018-11-22 CL CL2018003323A patent/CL2018003323A1/es unknown
- 2018-11-26 DO DO2018000257A patent/DOP2018000257A/es unknown
- 2018-11-29 MX MX2021009322A patent/MX2021009322A/es unknown
- 2018-11-29 PH PH12018502534A patent/PH12018502534B1/en unknown
- 2018-12-13 ZA ZA2018/08423A patent/ZA201808423B/en unknown
- 2018-12-26 EC ECSENADI201894790A patent/ECSP18094790A/es unknown
-
2020
- 2020-07-14 CY CY20201100646T patent/CY1124031T1/el unknown
-
2021
- 2021-10-25 JP JP2021173679A patent/JP7392211B2/ja active Active
- 2021-12-07 AU AU2021282409A patent/AU2021282409B2/en not_active Expired - Fee Related
-
2022
- 2022-02-18 AR ARP220100344A patent/AR124916A2/es unknown
-
2023
- 2023-03-27 JP JP2023049450A patent/JP7622122B2/ja active Active
-
2024
- 2024-04-16 AU AU2024202468A patent/AU2024202468A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517455A5 (OSRAM) | ||
| RU2021127810A (ru) | Замещенные гетероарилом пиридины и способы применения | |
| JP2020516671A5 (OSRAM) | ||
| JP2018535999A5 (OSRAM) | ||
| JP2017506237A5 (OSRAM) | ||
| RU2392275C2 (ru) | Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов | |
| RU2454415C2 (ru) | Производное индола | |
| JP5261383B2 (ja) | ヒトプロテインチロシンホスファターゼ阻害剤および使用法 | |
| JP2010513397A5 (OSRAM) | ||
| JP2010533158A5 (OSRAM) | ||
| JP2007523142A5 (OSRAM) | ||
| RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
| JP2013519680A5 (OSRAM) | ||
| RU2009102537A (ru) | Ингибиторы белок-тирозинфосфатазы человека и способы применения | |
| JP2015533157A5 (OSRAM) | ||
| JP2006503081A5 (OSRAM) | ||
| JP2008501673A5 (OSRAM) | ||
| JP2018507234A5 (OSRAM) | ||
| JP2008526866A5 (OSRAM) | ||
| JP2007308471A5 (OSRAM) | ||
| JP2006502134A5 (OSRAM) | ||
| JP2009544742A5 (OSRAM) | ||
| RU2010142229A (ru) | Производное циклопентилакриламида | |
| JP2006516251A5 (OSRAM) | ||
| RU2016111138A (ru) | Гетероциклические соединения и способы их применения |